Get notified when RADX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- No Minimum Offering Amount Required (new) — The company may raise far less than the $18.9 million maximum, or nothing at all, making the actual funding uncertain.
- Broad Discretion As to the Use of the Net Proceeds (new) — Management has wide latitude in spending the offering proceeds, and investors cannot assess whether the funds will be used effectively.
- Future Dilution As a Result of Future Equity Offerings (new) — The company may issue additional shares in the future at prices lower than this offering, which would dilute existing shareholders' ownership.
Radiopharm Theranostics launches up to $18.9M at-the-market ADS offering on Nasdaq
Filed December 23, 2025 · ~2 min read
Key Changes
-
high
Radiopharm Theranostics is offering ADSs (each representing 300 ordinary shares) with aggregate gross proceeds of up to $18.9 million via an at-the-market program through Leerink Partners.
The Offering verify on EDGAR → -
high
The offering has no minimum amount; actual sales and proceeds are uncertain and may be far below the $18.9 million maximum.
Use of Proceeds verify on EDGAR → -
medium
Net proceeds are earmarked for drug development and general corporate purposes, with management retaining broad discretion, including possible acquisitions or joint ventures.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade RADX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify